Citius Pharmaceuticals, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Citius Pharmaceuticals, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q4 2010 to Q3 2024.
  • Citius Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 6.73M shares, a 11.2% increase year-over-year.
  • Citius Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 6.73M shares, a 11.2% increase from 2023.
  • Citius Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 6.05M shares, a 95.9% decline from 2022.
  • Citius Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 146M shares, a 34.5% increase from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 6.73M +675K +11.2% Jul 1, 2024 Sep 30, 2024 10-K 2024-12-27
Q2 2024 174M +20.1M +13.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 159M +12.8M +8.77% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 159M +12.7M +8.72% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 6.05M -140M -95.9% Jul 1, 2023 Sep 30, 2023 10-K 2024-12-27
Q2 2023 154M +7.65M +5.23% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 146M +210K +0.14% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 146M +199K +0.14% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 146M Jul 1, 2022 Sep 30, 2022 10-K 2023-12-29
Q2 2022 146M +8.98M +6.55% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 146M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 146M Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-10
Q2 2021 137M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q2 2014 18M 0 0% Apr 1, 2014 Jun 30, 2014 10-Q 2014-08-14
Q1 2014 18M 0 0% Jan 1, 2014 Mar 31, 2014 10-Q 2014-05-15
Q4 2013 18M 0 0% Oct 1, 2013 Dec 31, 2013 10-Q 2014-02-19
Q3 2013 18M 0 0% Jul 1, 2013 Sep 30, 2013 10-K 2014-02-06
Q2 2013 18M 0 0% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-14
Q1 2013 18M 0 0% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-15
Q4 2012 18M 0 0% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-19
Q3 2012 18M 0 0% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-06
Q2 2012 18M 0 0% Apr 1, 2012 Jun 30, 2012 10-Q 2013-09-18
Q1 2012 18M 0 0% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-13
Q4 2011 18M 0 0% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-08
Q3 2011 18M Jul 1, 2011 Sep 30, 2011 10-K 2013-01-15
Q2 2011 18M Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-17
Q1 2011 18M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-11
Q4 2010 18M Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.